Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Ltd., commonly known as Sun Pharma, is a leading global pharmaceutical company headquartered in India. Established in 1993, the company has grown to become one of the largest specialty generic pharmaceutical manufacturers in the world, with a strong presence in North America, Europe, and emerging markets. Sun Pharma focuses on a diverse range of therapeutic areas, including cardiology, psychiatry, neurology, and dermatology. Its core products encompass a wide array of generic medications, specialty pharmaceuticals, and over-the-counter products, distinguished by their high quality and affordability. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of innovative therapies. With a commitment to research and development, Sun Pharma has positioned itself as a key player in the global pharmaceutical landscape, recognised for its excellence in manufacturing and a strong market presence.
DitchCarbon Score
How does Sun Pharmaceutical Industries's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sun Pharmaceutical Industries's score of 50 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sun Pharmaceutical Industries's reported carbon emissions
In 2025, Sun Pharmaceutical Industries, headquartered in India, reported significant carbon emissions, with Scope 1 emissions totalling approximately 156,242,000 kg CO2e and Scope 2 emissions at about 236,080,000 kg CO2e. This reflects a commitment to transparency in their environmental impact, as they have disclosed emissions data for both Scope 1 and Scope 2. For the previous year, 2024, the company recorded Scope 1 emissions of around 111,175,000 kg CO2e and Scope 2 emissions of approximately 237,766,000 kg CO2e. In 2023, emissions were reported at 122,306,000 kg CO2e for Scope 1 and 261,803,000 kg CO2e for Scope 2. Sun Pharmaceutical has set an ambitious target to achieve a 35% reduction in both Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. This commitment is part of their broader sustainability strategy, which aims to mitigate their carbon footprint and enhance environmental responsibility. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Overall, Sun Pharmaceutical Industries is actively working towards reducing its carbon emissions and demonstrating a commitment to climate action within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sun Pharmaceutical Industries is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
